Application of oncolytic virus or combination of oncolytic virus and PD-1 monoclonal antibody in pancreatic cancer treatment
The invention relates to the technical field of medicines, and aims to provide application of a novel oncolytic virus VG161 in treatment of pancreatic cancer and application of the novel oncolytic virus VG161 combined with PD-1 in treatment of pancreatic cancer. Through an in-vitro cell test, the VG161 single drug can be effectively copied and passaged after being infected with a pancreatic cancer cell line BxPC-3, and exogenous immune enhancement factors IL-12 and IL-15 carried by the VG161 single drug and PD-L1 antagonistic peptide are stably expressed; in an immune sound mouse pancreatic cancer BxPC-3 bilateral transplantation tumor model, the VG161 and a VG161 and PD-1 monoclonal antibody combined medication group both show a strong oncolytic effect, not only can effectively inhibit tumors on an injection side in a tumor, but also has a strong immunosuppressive effect on tumors on a non-injection side, which indicates that the VG161 can start systemic anti-tumor immune response, and can be used for preparing a medicine for treating pancreatic cancer. And after being combined with a PD-1 monoclonal antibody, the anti-tumor effect is further improved. The invention provides a new treatment scheme for clinical treatment of pancreatic cancer, and has positive popularization and application values..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 09. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LIANG TINGBO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-12-09, Last update posted on www.tib.eu: 2023-10-09, Last updated: 2023-10-13 |
|---|
| Patentnummer: |
CN115444868 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016861647 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016861647 | ||
| 003 | DE-627 | ||
| 005 | 20231013134259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016861647 | ||
| 035 | |a (EPA)CN115444868 | ||
| 035 | |a (EPA)84294567 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LIANG TINGBO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of oncolytic virus or combination of oncolytic virus and PD-1 monoclonal antibody in pancreatic cancer treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-12-09, Last update posted on www.tib.eu: 2023-10-09, Last updated: 2023-10-13 | ||
| 520 | |a The invention relates to the technical field of medicines, and aims to provide application of a novel oncolytic virus VG161 in treatment of pancreatic cancer and application of the novel oncolytic virus VG161 combined with PD-1 in treatment of pancreatic cancer. Through an in-vitro cell test, the VG161 single drug can be effectively copied and passaged after being infected with a pancreatic cancer cell line BxPC-3, and exogenous immune enhancement factors IL-12 and IL-15 carried by the VG161 single drug and PD-L1 antagonistic peptide are stably expressed; in an immune sound mouse pancreatic cancer BxPC-3 bilateral transplantation tumor model, the VG161 and a VG161 and PD-1 monoclonal antibody combined medication group both show a strong oncolytic effect, not only can effectively inhibit tumors on an injection side in a tumor, but also has a strong immunosuppressive effect on tumors on a non-injection side, which indicates that the VG161 can start systemic anti-tumor immune response, and can be used for preparing a medicine for treating pancreatic cancer. And after being combined with a PD-1 monoclonal antibody, the anti-tumor effect is further improved. The invention provides a new treatment scheme for clinical treatment of pancreatic cancer, and has positive popularization and application values. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHEN YINAN |4 aut | |
| 700 | 0 | |a SONG WEI |4 aut | |
| 700 | 0 | |a YANG ZIFAN |4 aut | |
| 700 | 0 | |a GUO SIDA |4 aut | |
| 700 | 0 | |a WANG ZIJUN |4 aut | |
| 700 | 0 | |a LIN DANNI |4 aut | |
| 700 | 0 | |a LI YUWEI |4 aut | |
| 700 | 0 | |a LIANG XINGMEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 09. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:09 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84294567/publication/CN115444868A1?q=CN115444868 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 09 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 09 |c 12 | ||